Alvotech files 6-K

Alvotech announced on June 8, 2026, that its Biologics License Application (BLA) for AVT16, a proposed interchangeable biosimilar to Entyvio® (vedolizumab), has been accepted for review by the U.S. Food and Drug Administration. The company also furnished its unaudited condensed consolidated interim financial statements for the three months ended March 31, 2026.